Label change history

This page is a reference summary of published evidence and regulatory documents. It is not a substitute for individual medical advice, and it is not a recommendation to take or avoid any medicine.

Medically reviewed by Dr. Sofia Lindqvist, · Last reviewed 11 August 2026

Last verified 11 August 2026. Next scheduled verification 11 November 2026.

A chronology of significant labelling changes and safety communications for the drugs covered on this site. This page exists because label changes are the most reliable signal of what regulators have learned about a drug since approval, and because they are difficult to find scattered across regulator websites.

Modafinil: pregnancy and reproductive safety

This is the most consequential sequence in modafinil’s regulatory history, and it remains unresolved between jurisdictions.
Date Regulator Action
April 2019 EMA Adopted labelling changes stating modafinil is suspected to cause congenital malformations when administered during pregnancy, and should not be used during pregnancy
June 2019 Health Canada Contraindicated Alertec in women who are pregnant or may become pregnant, citing association with major fetal congenital malformations including cardiac anomalies
June 2019 Ireland (HPRA) Labelling update and Dear Healthcare Professional letter
2019 Australia (TGA) Contraindicated in pregnancy
January 2020 UK Direct Healthcare Professional Communication on potential risk of congenital malformations during pregnancy
November 2020 MHRA Drug Safety Update: should not be used in pregnancy; effective contraception required during treatment and for two months after stopping
Ongoing FDA Has not required equivalent contraindication labelling. Public Citizen filed a petition urging contraindication for modafinil and armodafinil. Current status UNVERIFIED
78
prospective pregnancy cases in the registry
61
reported a live birth
9
presented with major congenital anomalies
5
regulators contraindicating by 2020

Underlying evidence. The signal arose from the US Nuvigil and Provigil Pregnancy Registry together with spontaneous postmarketing reports. Malformation types reported include congenital heart defects, hypospadias and orofacial clefts. A European case series additionally suggested a dose dependent reduction in birth weight and head circumference, though clinical relevance remains uncertain.

US pregnancy registry

Prospective cases plus spontaneous reports

EMA review, 2019

Suspected congenital malformations

National action

Canada, Ireland, Australia, UK contraindicate

FDA

No equivalent contraindication
Data generated largely in the United States led to stronger labelling outside it.
How the pregnancy signal moved from registry data to labelling, and where it stalled.
Every comparable regulator concluded contraindication was warranted on the basis of data generated substantially in the United States. Anyone reading only the FDA label may therefore be working from weaker warnings than international consensus supports.

Modafinil: dermatological and hypersensitivity reactions

Date Regulator Action
2006 FDA Rejected paediatric application, in part due to a confirmed case of Stevens Johnson syndrome in clinical trials
UNVERIFIED FDA Labelling updated to include serious skin reactions including Stevens Johnson syndrome, toxic epidermal necrolysis and DRESS
UNVERIFIED Multiple Labelling changes addressing angioedema and anaphylactoid reactions
Serious reactions
Postmarketing surveillance has documented serious skin reactions, and fatalities associated with drug hypersensitivity including DRESS have been reported for armodafinil.

Modafinil: patent and generic entry

Included because it explains the market structure and the timing of armodafinil’s development.
Date Event
1998 FDA approves Provigil (Cephalon)
2001 Composition patent expires per court filings. One source gives 2010 UNVERIFIED against the Orange Book, for US 4,927,855
2005 to 2006 Cephalon settles with Teva, Barr, Mylan and Ranbaxy, delaying generic entry to April 2012
2007 FDA approves armodafinil (Nuvigil)
April 2012 Generic modafinil enters the US market, per the settlement date rather than patent expiry
September 2012 Generic approved by Orion Pharms
April 2015 Reissue particle size patent would have expired
2016 Cephalon and Teva settle with 49 states and DC for $125 million over the pay for delay arrangements
A court subsequently deemed the additional patent invalid and unenforceable. Generic entry occurred six years after FDA exclusivity lapsed and three years before patent expiry, both dates set by settlement rather than by law.

Solriamfetol and pitolisant

Date Drug Event
2019 Solriamfetol FDA approval for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea
2019 Pitolisant FDA approval for cataplexy or excessive daytime sleepiness in narcolepsy
UNVERIFIED Pitolisant Paediatric indication added

Change log

Date Change Source
11 August 2026 Page created EMA, MHRA, Health Canada, HPRA, TGA, FDA

Frequently asked questions

Why track label changes at all?

Label changes are the most reliable signal of what regulators have learned about a drug since approval, and they are difficult to find scattered across regulator websites.

Do all regulators treat modafinil in pregnancy the same way?

No. The EMA, Health Canada, HPRA, TGA and MHRA moved to contraindication or equivalent warnings between 2019 and 2020. The FDA has not required equivalent contraindication labelling.

What did the pregnancy registry find?

The UK 2020 communication reported that of 78 prospective pregnancy cases, 61 reported a live birth, of which 9 presented with major congenital anomalies.

When did generic modafinil enter the US market?

April 2012, a date set by patent litigation settlements rather than by patent expiry.